Using light to control opioid receptors for better pain management
Genetically-Targeted Photo-Pharmacology for Native Opioid Receptors
This study is exploring new light-activated medicines that can help manage pain and mood by targeting specific brain receptors, aiming to provide safer and more effective options for people who need pain relief without the risks of addiction.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Weill Medical Coll of Cornell Univ NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10850805 on NIH RePORTER |
What this research studies
This research focuses on developing innovative compounds that can be activated by light to precisely control opioid receptors in the brain, which are crucial for managing pain and mood. By creating photoswitchable compounds, the researchers aim to improve the effectiveness of pain relief while minimizing the risks of addiction and side effects associated with traditional opioid treatments. The approach involves advanced techniques in chemistry and pharmacology to design and test these new compounds, potentially leading to safer and more effective pain management options for patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals suffering from chronic pain or mood disorders who may benefit from improved analgesic therapies.
Not a fit: Patients who do not experience pain or mood disorders may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new pain management therapies that are safer and more effective than current opioid medications.
How similar studies have performed: While the use of photopharmacology is a novel approach, similar strategies in targeting receptors have shown promise in other areas of research.
Where this research is happening
New York, United States
- Weill Medical Coll of Cornell Univ — New York, United States (Active)
Researchers
- Principal investigator: Levitz, Joshua — Weill Medical Coll of Cornell Univ
- Study coordinator: Levitz, Joshua
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.